Gemini Therapeutics and Disc Medicine Announce Definitive Merger Agreement
August 10, 2022
Gemini Therapeutics (Gemini) and Disc Medicine (Disc) entered into a definitive, all-stock merger agreement to combine the companies into a NASDAQ-listed, clinical-stage biopharmaceutical focused on advancing Disc’s hematology pipeline. The merged company is expected to have about $175 million in cash at closing, including $53.5 million from a concurrent financing led by Access Biotechnology and including OrbiMed and other healthcare investors, with the merger expected to close in Q4 2022.
- Buyers
- Gemini Therapeutics, Inc., Access Biotechnology, OrbiMed, Atlas Venture, 5AM Ventures, Novo Holdings A/S, Arix Bioscience, Rock Springs Capital, Janus Henderson Investors, Healthcare investors syndicate led by Access Biotechnology
- Targets
- Disc Medicine, Inc.
- Industry
- Healthcare Services
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.